MD on NYSE

Pediatrix Medical Group

Logo: pediatrix.com3

American physician-led national medical group.1

Price unavailable

Last updated Oct 18, 2026.

Overview

1979Founded1

Compare with Magellan Health, Select Medical or Encompass Health, or pick any stock.

  • TickerMD on NYSE1
  • IndustryServices-Hospitals1
  • HeadquartersSunrise1
  • Websitewww.pediatrix.com
  • Incorporated inFL4
  • Business address1301 Concord Terrace, Sunrise, Fl 333234
  • Filer categoryLarge accelerated filer4

See how the biggest companies compare on our leaderboards

Pediatrix Medical Group image from its website
Image: pediatrix.com3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

10.9%Operating margin5
8.6%Net margin5
-4.9%Revenue growth, 20255
19.1%Return on equity5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Health Care, Patient Service brought in 85% of the revenue Pediatrix Medical Group broke down this way in fiscal 2025.

  1. Health Care, Patient Service$1.6B585%down 5% from 2024
  2. Hospitals Contracts$271.1M514%down 5% from 2024
  3. Product and Service, Other$12.2M51%up 364% from 2024
Products and services by year
Products and services202320242025
Health Care, Patient Service$1.7B$1.7B$1.6B
Hospitals Contracts$275.7M$286.7M$271.1M
Product and Service, Other$2.6M$2.6M$12.2M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Other costs89¢$1.7B
  • Income tax3¢$51.0M
  • Profit9¢$165.4M

Out of $1.9B in revenue.5

Where each dollar of operating cash went, fiscal 2025

  • Share buybacks32¢$86.7M
  • Kept or used elsewhere68¢$184.4M

Out of $271.1M of cash from operations.5

Financial statements

Revenue67895$1.9B in 2025+8% since 2019
0$1.0B$2.0B$3.0B2019: $1.8B$1.8B20192020: $1.7B$1.7B2020−3%2021: $1.9B$1.9B2021+10%2022: $2.0B$2.0B2022+3%2023: $2.0B$2.0B2023+1%2024: $2.0B$2.0B2024+1%2025: $1.9B$1.9B2025−5%
Operating income67895$208.8M in 2025+22% since 2019
-$100.0M0$100.0M$200.0M$300.0M2019: $171.8M$171.8M20192020: $98.1M$98.1M2020−43%2021: $202.9M$202.9M2021+107%2022: $172.7M$172.7M2022−15%2023: $7.3M$7.3M2023−96%2024: -$68.7M-$68.7M20242025: $208.8M$208.8M2025
Net income67895$165.4M in 2025
-$1.5B-$1.0B-$500.0M0$500.0M2019: -$1.5B-$1.5B20192020: -$796.5M-$796.5M2020−47%2021: $131.0M$131.0M20212022: $66.3M$66.3M2022−49%2023: -$60.4M-$60.4M20232024: -$99.1M-$99.1M2024+64%2025: $165.4M$165.4M2025

Every line of the income statement as filed: the last 3 fiscal years, latest first.5

Period ending2025-12-312024-12-312023-12-31
Net revenue$1.9B$2.0B$2.0B
Practice salaries and benefits$1.3B$1.4B$1.4B
Practice supplies and other operating expenses$79.3M$117.7M$124.8M
General and administrative expenses$240.8M$238.4M$227.5M
Depreciation and amortization$21.8M$32.2M$36.2M
Transformational and restructuring related expenses$22.3M$64.3M$2.2M
Goodwill impairment$150.6M$148.3M
Long-lived asset impairments$27.8M$0
Loss on disposal of businesses$0$9.7M$0
Total operating expenses$1.7B$2.1B$2.0B
Income (loss) from operations$208.8M-$68.7M$7.3M
Investment and other income$19.0M$5.8M$4.3M
Net gain on investments in divested businesses$20.9M$0$0
Interest expense-$36.0M-$40.7M-$42.1M
Impairment of strategic investment$0-$20.0M
Equity in earnings of unconsolidated affiliate$3.6M$2.3M$2.1M
Total non-operating income (expenses)$7.6M-$32.6M-$55.7M
Income (loss) before income taxes$216.4M-$101.3M-$48.4M
Income tax (provision) benefit-$51.0M$2.3M-$12.0M
Net income (loss)$165.4M-$99.1M-$60.4M
Unrealized holding gain on investments, net of tax of $526, $374 and $527$1.7M$1.1M$1.5M
Total comprehensive income (loss)$167.1M-$97.9M-$58.9M
Basic$1.97-$1.19-$0.73
Diluted$1.94-$1.19-$0.73
Basic84.1M shares83.3M shares82.2M shares
Diluted85.3M shares83.3M shares82.2M shares
Net of Tax$525.0K$374.0K$527.0K

Compare Pediatrix Medical Group with another company

Leadership

Who has led Pediatrix Medical Group, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Roger Medel Md.2006–2020
  2. Mark S. Ordan2020–2023
  3. James D. Swift2023–2024

President

  1. Joseph M. Calabro2006–2019
  2. Michael D. Stanley2012–2016
  3. Karl B. Wagner2016

Chief financial officer

  1. Karl B. Wagner2006–2009
  2. Vivian Lopez-Blanco2010–2018
  3. Stephen D. Farber2018–2020
  4. C. Marc Richards2020–2024
  5. Kasandra H. Rossi2024–now

Chief operating officer

  1. Joseph M. Calabro2006–2018
  2. William C. Hawk2013–2015
  3. James D. Swift2022
  4. Curtis Pickert2023–2024
19801990200020102020
Board members and other officers (36)

Former names

  • MEDNAX, INC.Dec 22, 2008 to Jun 21, 20224
  • PEDIATRIX MEDICAL GROUP INCAug 8, 1996 to Jan 2, 20094

Timeline

  1. Mar 3, 2023New chief executive James D. Swift becomes CEO13
  2. Jul 14, 2020New chief executive Mark S. Ordan becomes CEO14
  3. Jan 5, 2006New chief executive Roger Medel Md. becomes CEO15
  4. 1979Founded Founded1

Filings

279 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 44 major events, 135 insider forms, 37 large holders, 43 other. The latest 20:

  1. Sep 14, 2026144 EDGAR
  2. Sep 14, 2026144 EDGAR
  3. Sep 14, 20264 EDGAR
  4. Sep 10, 2026144 EDGAR
  5. Sep 3, 2026SCHEDULE 13G EDGAR
  6. Sep 3, 2026SCHEDULE 13G EDGAR
  7. Sep 3, 2026SCHEDULE 13G/A EDGAR
  8. Aug 18, 20264 EDGAR
  9. Aug 14, 2026144 EDGAR
  10. Aug 14, 20264 EDGAR
  11. Aug 14, 20264 EDGAR
  12. Aug 14, 20264 EDGAR
  13. Aug 14, 20264 EDGAR
  14. Aug 14, 20264 EDGAR
  15. Aug 14, 20264 EDGAR
  16. Aug 14, 20264 EDGAR
  17. Aug 14, 20264 EDGAR
  18. Aug 4, 202610-Q EDGAR
  19. Aug 4, 20268-K EDGAR
  20. Jul 24, 20268-K EDGAR

The 279 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 37 such filings since October 2021, the latest 10:

  1. Sep 3, 2026SCHEDULE 13G
  2. Sep 3, 2026SCHEDULE 13G
  3. Sep 3, 2026SCHEDULE 13G/A
  4. Jul 14, 2026SCHEDULE 13G
  5. Apr 30, 2026SCHEDULE 13G
  6. Apr 29, 2026SCHEDULE 13G
  7. Mar 27, 2026SCHEDULE 13G/A
  8. Jun 3, 2025SCHEDULE 13G/A
  9. May 14, 2025SCHEDULE 13G/A
  10. Feb 13, 2025SCHEDULE 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.13,714,275$347.4M0.0%+139,902
Vanguard Portfolio Management LLC5,985,147$151.6M0.0%−168,979
Dimensional Fund Advisors LP4,220,311$106.9M0.0%+363,396
Vanguard Capital Management LLC3,620,040$91.7M0.0%−36,281
State Street Corp3,533,248$89.5M0.0%+154,748
Victory Capital Management Inc3,416,913$86.6M0.0%−425,020
Wasatch Advisors LP2,498,884$63.3M0.4%+448,360
Geode Capital Management, LLC2,226,028$56.4M0.0%+38,061
American Century Companies Inc2,192,017$55.5M0.0%−1,733,349
Fuller & Thaler Asset Management, Inc.1,721,451$43.6M0.1%+492,020
Allspring Global Investments Holdings, LLC1,618,910$42.3M0.1%+643,777
D. E. Shaw & Co., Inc.1,613,100$40.9M0.0%−95,333
Rockefeller Capital Management L.P.1,338,592$33.9M0.1%+576,095
Morgan Stanley1,328,477$33.7M0.0%+77,852
Charles Schwab Investment Management Inc1,294,185$32.8M0.0%−149,206
Renaissance Technologies LLC1,287,300$32.6M0.0%−245,000
Invesco Ltd.1,173,609$29.7M0.0%+251,432
Public Sector Pension Investment Board987,860$25.0M0.1%+566,451
Northern Trust Corp934,307$23.7M0.0%+34,037
Royce & Associates LP914,348$23.2M0.2%+235,578
Silvercrest Asset Management Group LLC912,380$23.1M0.2%−58,230
Nuveen, LLC868,272$22.0M0.0%−84,827
Goldman Sachs Group Inc825,636$20.9M0.0%−25,828
Bridgeway Capital Management, LLC761,642$19.3M0.3%+9,866
Fmr LLC741,386$18.8M0.0%−1,526,048

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

1 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Oct 15, 2019Donna Shalala, HouseSale$50,001 - $100,000+133.4%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61